AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-144134480/tysabri-two-year-phase.html" title="Facts and information about Tysabri two-year Phase III multiple sclerosis clinical trial results and safety evaluation published in New England Journal of Medicine; Tysabri currently under review with US and European Regulatory Authorities.">Tysabri two-year Phase III multiple sclerosis clinical trial results and safety evaluation published in New England Journal of Medicine; Tysabri currently under review with US and European Regulatory Authorities.</a>
Close
Set up an RSS feed that alerts you when new articles from Chemical Business Newsbase are available.
Frequently asked questions about RSS feeds
Tysabri two-year Phase III multiple sclerosis clinical trial results and safety evaluation published in New England Journal of Medicine; Tysabri currently under review with US and European Regulatory Authorities.
(From Chemical Business NewsBase - Press Release)
Biogen Idec and Elan Corp plc have announced that two-year results from the two Phase III clinical trials evaluating Tysabri (natalizumab) for patients with relapsing forms of multiple sclerosis (MS), as well as data from the comprehensive safety evaluation of the product were published for the first time in The New England Journal of Medicine. Two-Year AFFIRM Phase III monotherapy data showed that treatment with Tysabri …
Related articles from newspapers, magazines, journals, and more
-
- Lucentis shows significant vision benefits in pivotal Phase III data...
-
News wire article from: Europe Intelligence Wire
October 4, 2006
700+ words
-
- PRESS RELEASE: Shearwater announces publication of Pegasys Phase III trial...
-
News wire article from: Chemical Business Newsbase
December 11, 2000
700+ words
-
- Stelara shows greater efficacy than etanercept for treatment of moderate to...
-
News wire article from: Chemical Business Newsbase
January 14, 2010
700+ words
-
- New England Journal of Medicine publishes Phase III results of Velcade...
-
News wire article from: Chemical Business Newsbase
August 27, 2008
700+ words
-
- InterMune announces New England Journal of Medicine publication of Phase III...
-
News wire article from: Asia Africa Intelligence Wire
January 7, 2004
700+ words
